ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs MXN
20.42875
0.76%
Brent Oil
76.995
-0.25%
Bitcoin
99,745.67
-2.85%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) Noticias

CGEN

Compugen (CGEN)

Compugen Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CGEN
FechaHoraFuenteTítuloSímboloCompañía
08/01/202506:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
08/01/202506:00PR Newswire (US)Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsNASDAQ:CGENCompugen Ltd
27/11/202406:00PR Newswire (US)Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNASDAQ:CGENCompugen Ltd
12/11/202406:00PR Newswire (US)Compugen Reports Third Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
11/11/202406:00PR Newswire (US)Compugen to Participate in Stifel 2024 Healthcare ConferenceNASDAQ:CGENCompugen Ltd
05/11/202408:00PR Newswire (US)Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024NASDAQ:CGENCompugen Ltd
29/10/202406:00PR Newswire (US)Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:CGENCompugen Ltd
07/10/202406:00PR Newswire (US)Compugen to Present New Clinical Data at SITC 2024NASDAQ:CGENCompugen Ltd
09/09/202406:00PR Newswire (US)Compugen to Present at Single Cell Genomics 2024 ConferenceNASDAQ:CGENCompugen Ltd
29/08/202406:00PR Newswire (US)Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CGENCompugen Ltd
06/08/202406:00PR Newswire (US)Compugen Reports Second Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
29/07/202406:00PR Newswire (US)Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsNASDAQ:CGENCompugen Ltd
23/07/202406:00PR Newswire (US)Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024NASDAQ:CGENCompugen Ltd
17/06/202406:00PR Newswire (US)Compugen to Present at Upcoming Antibody Industrial SymposiumNASDAQ:CGENCompugen Ltd
30/05/202406:00PR Newswire (US)Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigNASDAQ:CGENCompugen Ltd
20/05/202406:00PR Newswire (US)Compugen Reports First Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
20/05/202405:59IH Market NewsU.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices DipNASDAQ:CGENCompugen Ltd
16/05/202406:00PR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialNASDAQ:CGENCompugen Ltd
15/05/202406:00PR Newswire (US)Compugen Appoints David Silberman as Chief Financial OfficerNASDAQ:CGENCompugen Ltd
06/05/202406:00PR Newswire (US)Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024NASDAQ:CGENCompugen Ltd
25/04/202406:00PR Newswire (US)Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024NASDAQ:CGENCompugen Ltd
10/04/202406:00PR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503NASDAQ:CGENCompugen Ltd
03/04/202406:00PR Newswire (US)Compugen to Participate in Two Upcoming Investor ConferencesNASDAQ:CGENCompugen Ltd
11/03/202406:00PR Newswire (US)Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer ImmunotherapyNASDAQ:CGENCompugen Ltd
06/03/202406:00PR Newswire (US)Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024NASDAQ:CGENCompugen Ltd
05/03/202415:06Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:CGENCompugen Ltd
05/03/202406:00PR Newswire (US)Compugen Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:CGENCompugen Ltd
05/03/202405:05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:CGENCompugen Ltd
26/02/202406:00PR Newswire (US)Compugen to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:CGENCompugen Ltd
20/02/202406:00PR Newswire (US)Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024NASDAQ:CGENCompugen Ltd
 Showing the most relevant articles for your search:NASDAQ:CGEN

Su Consulta Reciente

BIT
XSLR
Xtrackers Ie Physical Si...
BIT
UC3K2K
Unicredit Bank
BIT
P1XD91
NLBNPIT1XD91 20991231 10...
BIT
P1KT72
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados